NCT02497235View on ClinicalTrials.gov

A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

January 31, 2016

Conditions
Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
Interventions
DRUG

TAK-935

TAK-935 oral solution.

DRUG

[18F]MNI-792 (tracer)

\[18F\]MNI-792 injection.

Trial Locations (1)

Unknown

New Haven

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY